Abstract
Introduction
An epidemiological link has been established between chronic HCV infection and Type 2 Diabetes. The incidence of Type 2 Diabetes among chronic HCV patients was significantly higher than that in general population; (50% versus 14.5%) respectively. 1 The development of progressive insulin resistance impaired fasting glucose and/or frank Type 2 Diabetes (IFG/DM) was higher in chronic HCV patients than in general population. 2 It was postulated that, the presence of HCV core RNA in the circulation; triggers a multistep vicious cycle of metabolic derangement starting with a decreased expression of hepatic insulin receptor substrates 1 and 2 (IRS1 and IRS2) on hepatocytes leading to progressive insulin resistance and impaired glucose tolerance. 3 Kawaguchi et al 4 have found that, HCV directly causes insulin resistance through HCV core protein elicited proteasomal degradation of insulin receptor substrates and subsequent inactivation of intracellular insulin signaling molecules such as AKT. Additionally, tumor necrosis factor α and/or triglyceride accumulation induced nuclear factor-Kabba B activation in the liver is shown to play a role in insulin resistance in chronic HCV patients.
These changes are specific for chronic HCV infection and are not associated with infection by other hepatic viruses (HBV), suggesting an HCV induced intrinsic defect in hepatocytes independent from liver injury or autoimmunity. 5 In 2001, Cimino et al 6 described the interactions between chronic HCV infection, insulin resistance, Type 2 Diabetes and hepatosteatosis as a metabolic syndrome observed in chronic HCV patients. The progress of hepatic damage; (steatosis/fibrosis) scores was inversely proportional to plasma cholesterol levels and directly proportional to plasma insulin levels. Fibrosis is the hallmark of hepatic cirrhosis, of which worsening is probably the best surrogate marker for progression of chronic liver disease in chronic HCV patients. 7 Douglas and George (2009) 8 reported that; insulin resistance (IR) is most strongly associated with HCV infection, and its faster progression to fibrosis and cirrhosis in chronic HCV patients that may culminate in liver cell failure and hepatocellular carcinoma.
HCV is responsible for approximately 50% of hepatosteatosis cases. 9 Additionally, chronic HCV infection has an impact on lipid metabolism; lipoatrophy, peripheral (limb) wasting, increase hepatic handling and storage of fats. Lack of insulin sensitivity and an insulin resistance state activate hormone dependant lipase; with excessive mobilization of peripheral fats to the liver and hepatosteatosis. Characteristically, these patients have low plasma cholesterol and triglyceride levels. 10, 11 The aim of the study was to investigate the impacts of HCV infection on glucose and lipid metabolism and its correlation-if any-with body mass index (BMI) and hepatosteatosis in chronic HCV patients with and without Type 2 Diabetes.
patients and Methods
One hundred and three (103) chronic HCV patients were enrolled-none consecutively-in a retrospective observational study. They were either inpatients in the internal medicine department or were regularly attending HCV specialized out patients clinic, at Ain Shams University Hospital, in the period between January 2006 to September 2007.
Full history taking, thorough clinical examination, routine laboratory investigations including complete liver function tests and abdominal U/S were performed on all patients. Obese patients, patients with other concomitant viral infections (HBV), alcoholics, autoimmune hepatitis, hepatorenal syndrome and patients with hepatic focal lesions were all excluded from the study. Informed written consent were obtained from all participants and the study was approved by Ain Shams University Hospitals medical ethics committee (FMASU REC). HCV infection was diagnosed by the detection of anti-HCV antibody using the 3rd generation ELISA test and confirmed by qualitative polymerase chain reaction (PCR 14 Pelvic abdominal ultrasonography (U/S) was performed on all patients after an overnight fast and with the usual preparations. Aloka 3.5 Mega Hertz curved probe was used to examine; liver size, parenchymal echogenisity, enhancement, portal vein caliber and the billiary system.
Laboratory Investigations
Seven ml of venous blood was withdrawn from each patient after an overnight fast. Three ml was taken on EDTA for complete blood count (CBC) using an automated cell counter (Advial120), erythrocyte sedimentation rate (ESR) by the Westergren method and HbA1C by the quantitative colouremetric determination of glycosylated Hb in whole blood using the Stanbio Kit (1261 Northmain Street. Boerne, Texas 78006. www.stanbio.com). Four ml was put in a sterile plain tube, blood was allowed to clot and serum was separated by centrifugation at 3000 rpm for 20 minutes and stored at −20 °C until used. Serum was used in the following investigations:
• Using the automated chemistry analyzer Synchron Bechman Coulter CX9ALX CX5 Delta; -Fasting and 2hr.pp serum glucose level.-Liver function tests: Alanine amino transferase (ALT), Aspartate amino transferase (AST), gamma glutamyle transpeptidase (γGT), Alkaline Phosphates (ALP).-Kidney function tests. -Lipid profile.
• Anti-HCV antibodies were detected by 3rd generation ELISA Diasorin S.A kit (Alcopenges Madrid, Fax 39.0161.487628).
• HCV infection was confirmed by qualitative polymerase chain reaction (PCR) using the COBAS Amplicore HCV monitor test (Roche Diagnostic System Inc. branch burg, NG).Using the PCR amplified product; genotype was determined by INNO-LIPA HCVII (innogenetics N.V. technologies park 6. 9052 Ghent Belgium).The steps were followed according to the manufacture instructions and genotypes were deduced by using the INNO-LIPA HCVII interpretation chart.
• Fasting serum insulin level was assayed by immune-enzymatic method: using ELISA technique (MEDGENIX ins-ELISA).
statistics
Analysis of data was done by an IBM computer using SPSS (statistical program for social science version 12). Description of quantitative variables as mean, SD and range. Unpaired t-test was used to 
Results
The results were statistically analyzed and presented in (5) tables and (4) figures. Diabetic chronic HCV patients have a significantly (p  0.05) higher incidence of cirrhosis, haematemesis, melena and ascitis than non diabetic chronic HCV patients. (Table 2) .
Of the 68 patients in group I 37 (54%) and 35 patients in group II, 21 patients (60%) had previously undergone liver biopsies; to assess the degree of hepatic fibrosis/steatosis before interferon therapy;
(for therapeutic purposes and not as a part of this research methodology).
Biopsy reports were examined retrospectively; steatosis/fibrosis scores were recorded. Steatosis was graded according to Brunt's classification 15 Liver fibrosis/cirrhosis was scored (0-6) according to Ishak scoring system. 16 There was significantly (P  0.05) higher fibrosis/steatosis scores in diabetic chronic HCV patients than in non diabetic chronic HCV patients, (Table 3) .
Liver enzymes (AST, ALT and γ GT) were significantly higher in diabetic chronic HCV patients than in non diabetic chronic HCV patients. However non-significant differences were found between the groups regarding synthetic liver functions.
Total Cholesterol, HDL and LDL were significantly lower (p  0.05) in chronic HCV patients with or without diabetes compared to diabetic patients without HCV infection (group III). Additionally, diabetic patients with chronic HCV have lower serum cholesterol and triglycerides levels than non diabetic patients with chronic HCV, however this did not reach a statistically significant level (p  0.05). Diabetic patients with chronic HCV infection have significantly higher FBS, 2hpp and HbA1C levels than diabetic patients without HCV infection (controls), (Table 4) . There were non-significant (P  0.05) differences regarding BMI between all studied groups. Diabetic chronic HCV patients (group I) have significantly higher (P  0.05) fasting plasma insulin levels, HOMA-IR and waist/hip ratio (insulin resistance state) than non diabetic chronic HCV patients. Moreover, chronic HCV patients even without diabetes (group II) have higher plasma insulin level and HMOA-IR than patients with diabetes only (group III), (Table 5 ).
Discussion
Recently, chronic HCV infection has been regarded as a metabolic syndrome rather than a simple viral infection. Metabolic complications were frequently observed in chronic HCV patients concerning glucose and lipid metabolism. 17 Both host and viral factors contribute to insulin resistance, glucose intolerance and steatohepatitis. Importantly, fibrosis progression is closely linked to the insulin resistance state and hepatic steatosis in chronic HCV patients.
18
Up to one third of chronic HCV patients develop Type 2 Diabetes. 19 In agreement with this statement, we have found that 66% of chronic HCV patients in the present study were found to have Type 2 Diabetes.
There were significantly higher plasma insulin levels, waist/hip ratio and insulin resistance states by HOMA-IR in chronic HCV patients whether they were diabetics or not than diabetic patients without HCV infection (controls). This insulin resistance state that presents, even in non diabetic chronic HCV patients, was not due to an increased BMI, as there was non-significant differences in BMI between all studied groups. Despite the presence of significant positive correlation between BMI and fasting plasma insulin level in groups I and III patients (diabetics with and without HCV infection), no correlation was found in group II patients (non diabetic chronic HCV patients), indicating a unique mechanism of insulin resistance and hyperinsulinaemia in chronic HCV patients other than an elevated BMI. refer it directly to the HCV core protein that inactivates intracellular insulin signaling molecules such as AKT.
In the present study, retrospective analysis of the available liver biopsies reports revealed that diabetic chronic HCV patients have a more advanced histopathological grade of hepatic damage (steatosis/ fibrosis scores) compared to non diabetic chronic HCV patients. Though, there was non-significant (p  0.05) differences regarding HCV disease duration between both groups. Additionally, we have found significant positive correlations between plasma insulin level with liver enzymes and steatosis scores in chronic HCV patients (whether they were diabetic or not). The higher the plasma insulin level and insulin resistance state the more likely the elevated liver enzymes, and steatosis/fibrosis score -markers for hepatic damage in chronic HCV patients. Our results were consistent with that of Moucari et al 24 who studied the association between insulin resistance, serum HCV RNA level and steatohepatitis scores in a large prospective cohort of chronic HCV patients. They concluded that insulin resistance and hyperinsulinaemia are specific features of chronic HCV infection, especially with genotypes 4 and 1 (the most prevalent types in Egypt) and it positively correlated with the degree of steatohepatitis in HCV patients. It is well known that steatohepatitis accelerates cirrhosis in chronic HCV patients. Similarly, Douglas and George 8 found that there was a positive correlation between steatosis scores and the progression of hepatic damage due to cirrhosis in chronic HCV patients. Significant positive correlation was found between fasting plasma insulin level and steatosis /fibrosis scores (r = 0.79, p  0.01). While negative correlation was found with total cholesterol (r = -0.61, p  0.05) in chronic hcV patients whether they were diabetic or not (Fig. 4) . Significant positive correlation was found between plasma insulin level and BMI in groups I and III patients, (r = 0.56 and 0.44 respectively, p  0.05) (diabetics with and without hcV infection). While, no correlation was found between them in group II patients (hcV only); (r = 0.06, p  0.05), (Fig. 3) . {X axis: Indicates the body mass index (BMI)}. Steatosis worsened the course of hepatitis C with faster progression to cirrhosis and which may culminate in liver cell failure and hepatocellular carcinoma.
Plasma insulin
Similarly, Hora et al 25 concluded that insulin resistance and hyperinsulinaemia in HCV patients may aggravate virus C induced hepatic damage by up regulating hepatic stellate cells to produce connective tissue growth factor which plays a major role in extra cellular matrix protein production (fibrin) and progressive hepatic fibrosis. Therefore, it is of a vital importance to prevent and control diabetes, obesity, insulin resistance and hyperinsulinaemia in chronic HCV patients. Interestingly, Kattab et al 26 have found that; Pioglutazone (an insulin sensitizer) improves the virological response to peg interferon/ribavirin therapy in genotype 4 chronic HCV patients with insulin resistance.
In the present study, diabetic patients with chronic HCV infection have poorly controlled diabetes with higher FBS, 2hpp blood sugar and HBA1C levels than diabetic patients without HCV infection in spite of the fact that both groups of patients were on regular oral hypoglycemic drugs. The incidence of diabetic nephropathy and neuropathy was found to be significantly higher in diabetics with HCV infections than diabetic patients without HCV infection. Chronic HCV infection may negatively affect the diabetes course and prognosis. This is in agreement with Crook et al 27 who reported that hepatitis C viral infection is a predictor of poor renal outcomes in diabetic patients with chronic HCV infection.
There was significant hypocholesterolemia (LDL/ HDL) in chronic HCV patients (with and without diabetes) compared to diabetic patients without HCV infection. The total cholesterol level was negatively correlated with plasma insulin levels and hepatosteatosis scores in chronic HCV patients. This was in keeping with the results of Lecube et al 10 and Liakina et al 11 as they found that lack of insulin sensitivity and insulin resistance state activates hormone dependant lipase; with excessive mobilization of peripheral fats to the liver and hepatosteatosis. Characteristically, these patients have low plasma cholesterol and triglyceride levels.
Importantly, in this study the incidence of liver cirrhosis was higher (41%) in diabetic chronic HCV than in non diabetic chronic HCV patients (25%). This agrees with the Lonardo et al 28 who investigated large numbers of chronic HCV patients in double blind cross sectional study; they concluded that, chronic HCV infection is associated with dysmetabolic syndrome impaired insulin signaling, insulin resistance, Type 2 Diabetes, steatohepatitis and impaired response to antiviral therapy. These metabolic derangements accelerate liver cirrhosis and hence increase the risk of hepatocellular carcinoma. They added that insulin resistance is the key step for the metabolic derangement that complicates the course of chronic HCV infection.
conclusion and Recommendations
There appears to be an association between Type 2 Diabetes Mellitus and chronic HCV infection as both may aggravate each other. Chronic HCV infection may be regarded as an independent risk factor for Type 2 Diabetes. HCV infection induces a state of insulin resistance, hyperinsulinemia and glucose intolerance (independent of BMI), which in turn might accelerate virus C induced steatohepatitis and hence a progression to cirrhosis. Dyslipidemia and hepatic steatosis were frequent complications in chronic HCV patients, whether they were obese or not. However, HCV patients with a higher BMI have an additional risk for aggressive hepatosteatosis and cirrhosis than those with normal BMI. The potential impacts of chronic HCV infection on glucose and lipid metabolism should be recognized in clinical care centers and addressed in future research studies. Chronic HCV patients should have a regular exercise program, diet, weight control and follow up to antagonize the insulin resistance state which is the key step of virus C induced diabetes , steatohepatitis and cirrhosis. HCV patients should have regular blood sugar testing and diabetic patients-in HCV endemic areas -should be screened for HCV infection.
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